This acquisition marks a significant consolidation in the cell therapy quality control sector, offering a more integrated solution for manufacturers and developers.
- Clean Cells acquires Stem Genomics, gaining advanced technologies like the iCS-digital platform and Stem-Seq panel.
- The deal combines genomic stability testing and karyotyping in Durham, NC, under a single leadership.
- The acquisition strengthens regulatory compliance capabilities amid increasing scrutiny of genomic integrity documentation.
- The combined entity provides a single-source solution for quality control in cell and gene therapy development.
- The stem cell assay market is projected to grow from $4.6 billion in 2025 to $10.27 billion by 2035.
Problem The cell therapy sector has been grappling with fragmented quality control processes, particularly in genomic stability testing and pluripotency monitoring. This fragmentation poses significant challenges for pharmaceutical manufacturers and biotech developers who require reliable, end-to-end solutions for cell therapy development. Additionally, regulatory scrutiny on genomic integrity documentation is intensifying, especially for therapies using induced pluripotent stem cells (iPSCs) targeting oncology, neurological diseases, and rare conditions.
Solution Clean Cells, a biopharma quality control services provider specializing in biologics GMP testing, has acquired Stem Genomics, a developer of advanced quality control technologies for stem cell therapy. This strategic move brings several key technologies under Clean Cells' umbrella: - **iCS-digital Platform**: A digital PCR-based assay capable of detecting over 90% of recurrent chromosomal abnormalities in stem cell cultures. - **Stem-Seq Panel**: A next-generation sequencing tool for genomic stability analysis. - **Pluri-digital Assay**: A method for monitoring pluripotency and differentiation.
The acquisition includes Stem Genomics' entire operations, encompassing its French entity and the US corporation, Stem Genomics Inc., based in Durham, North Carolina. This consolidation allows Clean Cells to merge genomic stability testing and karyotyping under one roof, leveraging the existing infrastructure of Karyologic, another Durham-based company acquired by Clean Cells in March 2022.
"Cell and gene therapy developers need reliable partners. With this deal, we are expanding our ability to support research teams from their early genomic stability testing through to cell banking and viral safety testing to GMP lot release." - Laurent Claisse, CEO of Clean Cells
Results The acquisition strengthens Clean Cells' position as a comprehensive quality control partner for cell and gene therapy developers. Key outcomes include: - **Expanded Service Offering**: The combined capabilities now provide a single-source solution for genomic stability testing, cell banking, viral safety testing, and GMP lot release data preparation. - **Enhanced Regulatory Compliance**: The integration of Stem Genomics' technologies allows Clean Cells to better address the tightening regulatory requirements around genomic integrity documentation. - **Operational Synergy**: By combining operations in Durham, North Carolina, Clean Cells can streamline processes and improve efficiency. Stem Genomics CEO Nicolas Chapal will lead the combined Stem Cell Business Unit. - **Market Positioning**: The acquisition aligns with analyst projections for the stem cell assay market, which is expected to grow from $4.6 billion in 2025 to $10.27 billion by 2035.
Ludovic Alonzi, Partner at ARCHIMED, the investment firm backing Clean Biologics, emphasized the strategic importance of the acquisition: "This deal positions the Clean Biologics group to cover the full quality control range for the fastest-growing segment of the biopharmaceutical market."
##
Is this your company?
This article features your business. Claim it to add your logo, contact details, and a link to your website — or upgrade to reach more buyers.
Did you know 80% of Press Releases trigger AI content warnings? Reach out and the M4S team can assist.